Gestrinone versus danazol as preoperative treatment for hysteroscopic surgery: a prospective, randomized evaluation.
OBJECTIVE
To compare danazol and gestrinone treatment as preoperative endometrial preparation for operative hysteroscopy.


METHODS
Prospective, randomized clinical study.


METHODS
University department of gynecological, obstetrical sciences and reproductive medicine.


METHODS
One hundred thirty-five patients with endouterine pathologies (endometrial polyps, submucous myoma, septate uterus).


METHODS
Patients pretreated with gestrinone (n = 68) and with danazol (n = 67) underwent operative hysteroscopy.


METHODS
Endometrial response to the medical pretreatment, side effects, procedure time, intraoperative bleeding, infusion volume, patient satisfaction.


RESULTS
Side effects were infrequent in both groups, though the patients' personal satisfaction was in favor of gestrinone. The rate of endometrial response was higher for the gestrinone group (97.1% vs. 83.6%). Operative time (mean +/- SD) was 12 +/- 1.8 and 15.2 +/- 1.9 minutes for the gestrinone and danazol groups, respectively. The gestrinone group showed a lower incidence of moderate bleeding (3% vs. 22.4%) and a lower infusion volume (2,100 +/- 200 mL vs. 2,400 +/- 250 mL). Regarding cervical dilatation time, no significant difference was found between the two groups (1.6 +/- 0.3 minutes vs. 1.5 +/- 0.4 minutes).


CONCLUSIONS
Both treatments are good ways to prepare the endometrium for operative hysteroscopy. However, the data suggest that gestrinone pretreatment is preferable to danazol.
Department of Gynecological, Obstetrical Sciences and Reproductive Medicine, University of Messina, Messina, Italy. otriolo@unime.it
Onofrio
O
Triolo
Antonio
A
De Vivo
Vincenzo
V
Benedetto
Salvatore
S
Falcone
Francesco
F
Antico
D000328:Adult; D003276:Contraceptives, Oral / Q000008:administration & dosage / Q000009:adverse effects; D003613:Danazol / Q000008:administration & dosage* / Q000009:adverse effects; D004717:Endometrium / Q000187:drug effects / Q000473:pathology / Q000601:surgery*; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005867:Gestrinone / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D015907:Hysteroscopy; D008875:Middle Aged; D011300:Preoperative Care / Q000379:methods*; D011446:Prospective Studies
D003276:Contraceptives, Oral; D004965:Estrogen Antagonists; D005867:Gestrinone; D003613:Danazol